Abstract
Within the past 5 years, F-18 fluorodeoxyglucose (FDG) PET/CT has become one of the more frequent imaging modalities in the management of patients with cancer of unknown primary origin. FDG PET/CT detects more sites of metastasis than other modolities, and in 20% to 40% of cases it discloses the site of the prima tumor. Its exact role is yet to be defined because of a lack of prospective clinical trials comparing the performance of PET/CT with conventional anatomic imaging modalities. This article reviews the available literature, attempts to place PET/CT using F-18-labeled FDG in clinical perspective and compares the combined modality with conventional anatomic imaging technologies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 239-244 |
| Number of pages | 6 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2009 |
Keywords
- Cancer of unknown origin
- PET/CT
- Unknown primary and PET/CT
- Unknown primary site
ASJC Scopus subject areas
- Oncology